EHPnet: Global Sports Alliance
نویسنده
چکیده
Background: Endostatin is a potent endogenous anti-angiogenic agent which inhibits tumour growth. A non-synonymous coding polymorphism in the Endostatin gene is thought to affect Endostatin activity. We aimed to determine the role of this Endostatin polymorphism in breast cancer pathogenesis and any influence on serum Endostatin levels in healthy volunteers. Endostatin protein expression on a breast cancer micro array was also studied to determine any relationship to genotype and to breast cancer prognosis. Methods: The 4349G > A (coding non-synonymous) polymorphism in exon 42 of the Endostatin gene was genotyped in approximately 846 breast cancer cases and 707 appropriate controls. In a separate healthy cohort of 57 individuals, in addition to genotyping, serum Endostatin levels were measured using enzyme linked immunosorbant assay (ELISA). A semi-quantitative assessment of Endostatin protein expression on immunostained tissue micro arrays (TMA) constructed from breast cancer samples of patients with genotype data was performed. Results: The rare allele (A) was significantly associated with invasive breast cancers compared to non-invasive tumours (p = 0.03), but there was no association with tumour grade, nodal status, vascular invasion or overall survival. There was no association with breast cancer susceptibility. Serum Endostatin levels and Endostatin protein expression on the tissue micro array were not associated with genotype. Conclusion: The Endostatin 4349A allele is associated with invasive breast cancer. The Endostatin 4349G > A polymorphism however does not appear to be associated with breast cancer susceptibility or severity in invasive disease. By studying circulating levels and tumour Endostatin protein expression, we have shown that any influence of this polymorphism is unlikely to be through an effect on the levels of protein produced. Published: 22 June 2007 BMC Cancer 2007, 7:107 doi:10.1186/1471-2407-7-107 Received: 29 December 2006 Accepted: 22 June 2007 This article is available from: http://www.biomedcentral.com/1471-2407/7/107 © 2007 Balasubramanian et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
منابع مشابه
Challenges Facing Global Health Networks: The NCD Alliance Experience; Comment on “Four Challenges that Global Health Networks Face”
Successful prevention and control of the epidemic of noncommunicable diseases (NCDs) cannot be achieved by the health sector alone: a wide range of organisations from multiple sectors and across government must also be involved. This requires a new, inclusive approach to advocacy and to coordinating, convening and catalysing action across civil society, best achieved by a broad-based network. T...
متن کاملOn global (strong) defensive alliances in some product graphs
A defensive alliance in a graph is a set $S$ of vertices with the property that every vertex in $S$ has at most one moreneighbor outside of $S$ than it has inside of $S$. A defensive alliance $S$ is called global if it forms a dominating set. The global defensive alliance number of a graph $G$ is the minimum cardinality of a global defensive alliance in $G$. In this article we study the global ...
متن کاملEHPnet: Global Surveillance
To increase the accessibility of drug-antibody complexes to tumours and to decrease non-specific
متن کاملEHPnet: Evolving Research
1 Université de Bourgogne, CNRS-UMR5548, Dijon, France, 2 INRA-UMR1272,Versailles, France, 3 Organic Chemistry, Hamburg University, Hamburg, Germany, 4 Department of Biology, Graduate School of Sciences, Kyushu University, Fukuoka, Japan, 5 Department of Applied Biology, Faculty of Textile Science, Kyoto Institute of Technology, Kyoto, Japan, 6 Faculty of Life Sciences, University of Manchester...
متن کامل